Intentar ORO - Gratis
South Korea poised to become MEDICAL AI POWERHOUSE
BioSpectrum Asia
|BioSpectrum Asia Sep 2023
When it comes to Al (Artificial Intelligence) in medical sciences - China and the USA dominate the field. However, South Korea has been steadily catching up. Home to renowned tech giants such as Samsung and LG Electronics, South Korea is positioning itself as a significant player in the medical Al domain. The country is making remarkable strides in deploying Al for medical imaging, diagnostics, drug development and healthcare. Let's look at South Korea's efforts in becoming a medical Al powerhouse.
South Korea is ramping up efforts to bolster AI development in life sciences.The country is implementing strategic initiatives, with a key focus on robust regulations. The country is actively revising its regulations in the AI domain to foster progress in this field. In May 2023, the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) and the United States Food and Drug Administration (USFDA) signed an MoU to accelerate medical product development using AI. In April 2023, the Ministry of Health and Welfare in South Korea introduced ‘The 1st Comprehensive Plan for Development and Support for the Medical Devices Industry (2023~2027). The plan’s key objectives include facilitating market entry for innovative technologies such as AI and digital solutions, rationalising regulations and systems, and promoting innovation among corporations in the medical devices sector.
South Korea along with experts from the UK and Singapore released a global guide for the use of artificial intelligence in medical care in 2021. The guide is designed to act as a benchmark for the liable use of AI, and enhance clarity and high standards for technological applications in the healthcare sector.
“Korea boasts a well-structured healthcare system, fostering active endeavours to enhance it through AI technology and expedite the adoption of precision medicine. Notably, major companies from various fields other than the healthcare industry have begun investing significant capital in bio-health and medical technology innovations. Moreover, both established pharmaceutical and medical device companies, as well as rapidly emerging medical startups, are fervently engaged in research and development (R&D) for innovative technologies and services. As a result, Korea’s medical AI market is experiencing rapid growth,” said
Esta historia es de la edición BioSpectrum Asia Sep 2023 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia
BioSpectrum Asia
Alphamab Oncology appoints Fei Wang as Chief Financial Officer
Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market
DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
PHCbi introduces LiCellGrow Cell Expansion System
PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences
CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala
Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation
Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Argo Biopharma ropes in Dr Gena Wang as CFO and CSO
China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust
The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Korea designs model for accurate and scalable drug-drug interaction prediction
A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.
1 min
BioSpectrum Asia April 2027
Translate
Change font size

